Beijing Wantai Biological Pharmacy Enterprise (603392.SH): Recombinant trivalent rotavirus subunit vaccine (E. coli) approved for clinical trials.

16:15 26/03/2026

WanTai Biotech (603392.SH) announced that its wholly-owned subsidiary, Xiamen WanTai Canghai Biotechnology Co., Ltd. (referred to as "WanTai Canghai"), has received the Drug Clinical Trial Approval Notice issued by the National Medical Products Administration for the recombinant trivalent rotavirus subunit vaccine (Enterovirus) and is approved to conduct clinical trials for the prevention of rotavirus gastroenteritis.

Beijing Wantai Biological Pharmacy Enterprise (603392.SH) announced that its wholly-owned subsidiary Xiamen Wantai Canghai Biotechnology Co., Ltd. (referred to as "Wantai Canghai") has received approval from the National Medical Products Administration for the clinical trial of the recombinant trivalent rotavirus subunit vaccine (Escherichia coli), allowing for clinical trials on the prevention of rotavirus gastroenteritis.

RUIXIN INT'L (00724) issues a profit warning, expecting a loss of approximately HK$10 million to HK$12 million for the fiscal year 20265, a decrease of approximately 71.2% to 76.0% compared to the previous year.

WG ENV TECH (01845) announced its performance for the year 2025, with a net loss attributable to shareholders of 63.146 million yuan, an increase of 30% compared to the previous year.

TENCENT (00700) spent HK$295 million on March 26 to repurchase 590,000 shares.

WG ENV TECH (01845) announced its performance for the year 2025, with a net loss attributable to shareholders of 63.146 million yuan, an increase of 30% compared to the previous year.

TENCENT (00700) spent HK$295 million on March 26 to repurchase 590,000 shares.